Berardinelli-Seip Congenital Lipodystrophy

Mendelian MONDO:0018883 Pathograph 35 Hereditary lipodystrophy Disorder of development or morphogenesis

Berardinelli-Seip congenital lipodystrophy is a rare autosomal recessive generalized lipodystrophy with near-total adipose tissue loss from birth or early infancy, muscular hypertrophy, severe insulin resistance, hypertriglyceridemia, hepatic steatosis, hepatomegaly, and early diabetes. The four established molecular subtypes are caused by biallelic pathogenic variants in AGPAT2, BSCL2, CAV1, and CAVIN1/PTRF. These genes converge on impaired triglyceride or phospholipid handling, lipid-droplet biology, adipocyte differentiation, and caveola formation in adipocytes. Failure to store triglycerides in adipose tissue diverts lipid to liver and skeletal muscle and combines with severe leptin deficiency to drive the metabolic phenotype. Treatment is supportive and metabolic, including dietary management, conventional diabetes and hyperlipidemia therapy, and metreleptin replacement for generalized lipodystrophy.

Ask OpenScientist

Ask a research question about Berardinelli-Seip Congenital Lipodystrophy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
8
Pathophys.
16
Phenotypes
35
Pathograph
4
Genes
5
Treatments
4
Subtypes
8
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0018883 Berardinelli-Seip congenital lipodystrophy
skos:exactMatch MONDO
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Berardinelli-Seip congenital lipodystrophy is inherited as an autosomal recessive disorder across the established molecular subtypes.
Autosomal recessive inheritance
Show evidence (2 references)
ORPHA:528 SUPPORT Other
"Autosomal recessive"
Orphanet records autosomal recessive inheritance.
PMID:11967537 SUPPORT Human Clinical
"Congenital generalized lipodystrophy is an autosomal recessive disorder"
The AGPAT2 discovery study states the autosomal recessive inheritance pattern.
◆

Subtypes

4
Type 1 (AGPAT2)
Type 1 congenital generalized lipodystrophy is the AGPAT2-associated form corresponding to OMIM 608594. AGPAT2 encodes a lysophosphatidic acid acyltransferase required for phosphatidic acid generation during triglyceride and glycerophospholipid biosynthesis in adipose tissue.
Show evidence (2 references)
PMID:26239609 SUPPORT Other
"type 1 is associated with AGPAT2 mutations"
The review defines CGL type 1 as the AGPAT2-associated subtype.
PMID:11967537 SUPPORT Human Clinical
"several different mutations of the gene (AGPAT2) encoding"
The AGPAT2 discovery study identified AGPAT2 mutations in affected individuals.
Type 2 (BSCL2/seipin)
Type 2 congenital generalized lipodystrophy is the BSCL2-associated form corresponding to OMIM 269700. BSCL2 encodes seipin, an endoplasmic-reticulum protein involved in lipid-droplet assembly, lipid homeostasis, and terminal adipocyte differentiation.
Show evidence (2 references)
PMID:26239609 SUPPORT Other
"associated with BSCL2 mutations; type 3 is associated"
The review defines CGL type 2 as the BSCL2-associated subtype.
PMID:11479539 SUPPORT Human Clinical
"encodes a protein (which we have called seipin)"
The BSCL2 discovery study identifies the seipin gene product in families linked to chromosome 11q13.
Type 3 (CAV1)
Type 3 congenital generalized lipodystrophy is the CAV1-associated form corresponding to OMIM 612526. CAV1 encodes caveolin 1, a core caveola component needed for caveola-mediated lipid handling and lipid-droplet integrity in adipocytes.
Show evidence (1 reference)
PMID:26239609 SUPPORT Other
"type 3 is associated with CAV1 mutations"
The review defines CGL type 3 as the CAV1-associated subtype.
Type 4 (CAVIN1/PTRF)
Type 4 congenital generalized lipodystrophy is the CAVIN1/PTRF-associated form corresponding to OMIM 613327. CAVIN1 was historically named PTRF and is required for caveola biogenesis and adipose tissue expandability.
Show evidence (1 reference)
PMID:26239609 SUPPORT Other
"type 4 is associated with PTRF mutations"
The review defines CGL type 4 as the PTRF/CAVIN1-associated subtype.
⚙

Pathophysiology

8
AGPAT2 acylglycerol synthesis defect
AGPAT2 pathogenic variants impair lysophosphatidic-acid acylation to phosphatidic acid, a key step in triacylglycerol and glycerophospholipid synthesis. In adipocytes this limits normal triglyceride synthesis and storage.
adipocyte link
AGPAT2 link
triglyceride biosynthetic process link ↓ DECREASED
lysophosphatidic acid acyltransferase activity link ↓ DECREASED
Downstream
Generalized adipose tissue loss Impaired adipocyte triglyceride synthesis and storage contributes to generalized adipose tissue loss.
Show evidence (2 references)
PMID:11967537 SUPPORT Human Clinical
"AGPAT2 enzyme catalyzes the acylation"
The AGPAT2 discovery paper defines the affected enzymatic step.
PMID:11967537 SUPPORT Human Clinical
"by inhibiting triacylglycerol synthesis and storage in adipocytes."
The paper links AGPAT2 mutations to impaired triacylglycerol storage in adipocytes.
BSCL2 seipin lipid-droplet dysregulation
BSCL2 encodes seipin, an endoplasmic-reticulum protein that participates in lipid-droplet assembly and terminal adipocyte differentiation. Loss of seipin disrupts regulated lipid-droplet biology and adipogenesis.
adipocyte link
BSCL2 link
fat cell differentiation link ↓ DECREASED lipid droplet organization link ↓ DECREASED
lipid droplet link
Downstream
Generalized adipose tissue loss Failed adipocyte differentiation and lipid-droplet maintenance reduces adipose tissue mass.
Intellectual disability BSCL2-associated disease has higher risk of intellectual impairment than AGPAT2-associated disease.
Show evidence (3 references)
PMID:11479539 SUPPORT Human Clinical
"variants are null mutations"
The BSCL2 discovery paper supports severe disruption of seipin in affected families.
PMID:22269949 SUPPORT Model Organism
"Bscl2(-/-) mice develop"
The mouse knockout model recapitulates severe white-adipose lipodystrophy.
PMID:22269949 SUPPORT In Vitro
"a striking failure in terminal"
Cell differentiation experiments support seipin loss as a terminal adipocyte differentiation defect.
CAV1 caveola and lipid-droplet defect
CAV1 encodes caveolin 1, a major caveola component. CAV1 deficiency disrupts caveola-dependent fatty-acid and cholesterol handling and reduces the ability of adipocytes to expand lipid droplets.
adipocyte link
CAV1 link
caveola assembly link ↓ DECREASED lipid droplet organization link ↓ DECREASED
Downstream
Generalized adipose tissue loss Defective caveola and lipid-droplet expansion impairs adipose tissue maintenance.
Show evidence (2 references)
PMID:26239609 SUPPORT Other
"Type 3 CGL, (OMIM #612526)"
The review identifies type 3 CGL as the CAV1-associated subtype.
PMID:26239609 SUPPORT Other
"enables the expansion of lipid droplet size"
The review links caveolin 1 to lipid-droplet expansion in adipocytes.
CAVIN1 caveola biogenesis defect
CAVIN1, historically named PTRF, is required for caveola biogenesis and caveola stabilization. Biallelic pathogenic variants cause type 4 CGL with progressive lipodystrophy and additional muscle and cardiac involvement.
adipocyte link
CAVIN1 link
caveola assembly link ↓ DECREASED
Downstream
Generalized adipose tissue loss Caveola biogenesis failure disrupts adipocyte lipid handling and tissue expandability.
CGL4 congenital myopathy CAVIN1/PTRF-associated type 4 disease includes congenital myopathy.
CGL4 elevated creatine kinase CAVIN1/PTRF-associated myopathy is accompanied by high serum creatine kinase.
CGL4 cardiac arrhythmia risk CAVIN1/PTRF-associated type 4 disease predisposes to serious ventricular arrhythmias.
Show evidence (2 references)
PMID:26239609 SUPPORT Other
"Type 4 CGL (OMIM #613327)"
The review identifies type 4 CGL as the PTRF/CAVIN1-associated subtype.
PMID:26239609 SUPPORT Other
"an essential factor in the biogenesis of caveolae"
The review states that PTRF/CAVIN1 is essential for caveola biogenesis.
Generalized adipose tissue loss
The shared cellular outcome is near-total loss of adipose tissue and inability to maintain normal triglyceride-storing adipocyte depots.
adipocyte link ↓ DECREASED
adipose tissue link
Downstream
Lipodystrophy Near-total adipose loss clinically manifests as generalized lipodystrophy.
Adipose tissue loss Loss of adipocytes produces the HPO adipose tissue loss phenotype.
Ectopic triglyceride accumulation Inability to store triglyceride in adipose tissue diverts lipid to non-adipose organs.
Hypoleptinemia-driven metabolic dysregulation Near-total adipose tissue loss markedly reduces leptin production.
Low leptin concentration Near-total adipose tissue loss lowers circulating leptin.
Skeletal muscle hypertrophy Loss of subcutaneous fat and the CGL body habitus present clinically as extreme muscularity or muscle hypertrophy.
Hypertrichosis Hypertrichosis is a recurrent syndromic feature of congenital generalized lipodystrophy, but the cached evidence does not resolve a single mechanism.
Show evidence (2 references)
ORPHA:528 SUPPORT Other
"generalized lipoatrophy with acromegaloid features"
Orphanet's definition supports generalized lipoatrophy as a core feature.
PMID:26239609 SUPPORT Other
"near complete lack of adipose tissue from"
The review describes near-complete adipose tissue absence in CGL.
Ectopic triglyceride accumulation
Because adipose tissue cannot efficiently store circulating triglycerides, excess lipid accumulates in liver and skeletal muscle, causing steatosis, hepatomegaly, hypertriglyceridemia, and downstream insulin resistance.
hepatocyte link cell of skeletal muscle link
liver link skeletal muscle tissue link
Downstream
Hepatic steatosis Ectopic triglyceride accumulation in hepatocytes produces hepatic steatosis.
Hepatomegaly Hepatic lipid accumulation contributes to liver enlargement.
Hypertriglyceridemia Impaired adipose storage and altered lipid handling contribute to circulating hypertriglyceridemia.
Insulin resistance Ectopic lipid accumulation is a major driver of severe insulin resistance.
Severe insulin resistance Hepatic steatosis and intramyocellular lipid accumulation contribute to the severe insulin-resistance mechanism, although the intervening molecular steps remain incompletely defined.
Show evidence (2 references)
PMID:26239609 SUPPORT Other
"The major mechanism for developing metabolic complications in CGL is related to the near total lack of adipose tissue"
The review states the central mechanism for metabolic complications.
PMID:26239609 SUPPORT Other
"spillover of excess triglycerides to other organs such as the liver and skeletal muscles"
The review explains ectopic triglyceride spillover into liver and skeletal muscle.
Hypoleptinemia-driven metabolic dysregulation
Near-total adipose tissue loss markedly lowers leptin levels. Severe leptin deficiency can increase appetite and worsen diabetes, hypertriglyceridemia, and hepatic steatosis.
Downstream
Insulin resistance Severe leptin deficiency worsens metabolic insulin resistance.
Hypertriglyceridemia Leptin deficiency worsens triglyceride dysregulation.
Diabetes mellitus Worsened metabolic derangement contributes to diabetes.
Show evidence (2 references)
PMID:26239609 SUPPORT Other
"Profound hypoleptinaemia further exacerbates metabolic"
The review links profound leptin deficiency to worsened metabolic derangements.
PMID:26239609 SUPPORT Other
"by inducing hyperphagia."
The review identifies hyperphagia as one mechanism of leptin-deficiency-mediated metabolic worsening.
Severe insulin resistance
Ectopic lipid accumulation and leptin deficiency produce extreme insulin resistance. This drives hyperinsulinemia, acanthosis nigricans, glucose intolerance, and diabetes.
insulin receptor signaling pathway link ↓ DECREASED
Downstream
Insulin resistance The mechanism directly produces the clinical insulin-resistance phenotype.
Hyperinsulinemia Pancreatic compensation for insulin resistance increases circulating insulin.
Diabetes mellitus Severe insulin resistance predisposes to diabetes mellitus.
Acanthosis nigricans Chronic insulin resistance can produce acanthosis nigricans.
Hypertrophic cardiomyopathy Severe cardiometabolic disease can include hypertrophic cardiomyopathy, but the cached evidence does not resolve a single intermediate mechanism.
Show evidence (2 references)
PMID:11967537 SUPPORT Human Clinical
"marked paucity of adipose tissue, extreme insulin resistance,"
The AGPAT2 discovery paper includes extreme insulin resistance in the clinical phenotype.
ORPHA:528 SUPPORT Other
"muscle hypertrophy, insulin resistance, hypertriglyceridemia"
Orphanet includes insulin resistance as a defining feature.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Berardinelli-Seip Congenital Lipodystrophy Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

16
Cardiovascular 2
Hypertrophic cardiomyopathy OCCASIONAL Hypertrophic cardiomyopathy (HP:0001639)
Show evidence (2 references)
ORPHA:528 SUPPORT Other
"HP:0001639 | Hypertrophic cardiomyopathy | Occasional (29-5%)"
Orphanet records hypertrophic cardiomyopathy as occasional.
PMID:12362029 SUPPORT Human Clinical
"hypertrophic cardiomyopathy were significant contributors"
The genotype-phenotype cohort identifies hypertrophic cardiomyopathy as a morbidity contributor.
CGL4 cardiac arrhythmia risk Arrhythmia (HP:0011675)
Show evidence (1 reference)
PMID:26239609 SUPPORT Human Clinical
"predisposition to serious arrhythmias such as catecholaminergic polymorphic ventricular tachycardia, long QT interval and sudden death"
The CGL review identifies serious arrhythmias and sudden death as CGL4-specific risks.
Digestive 2
Hepatomegaly VERY_FREQUENT Hepatomegaly (HP:0002240)
Show evidence (1 reference)
ORPHA:528 SUPPORT Other
"HP:0002240 | Hepatomegaly | Very frequent (99-80%)"
Orphanet records hepatomegaly as very frequent.
Hepatic steatosis OCCASIONAL Hepatic steatosis (HP:0001397)
Show evidence (2 references)
ORPHA:528 SUPPORT Other
"HP:0001397 | Hepatic steatosis | Occasional (29-5%)"
Orphanet records hepatic steatosis as occasional.
PMID:11967537 SUPPORT Human Clinical
"hypertriglyceridemia, hepatic steatosis and early onset of diabetes."
The AGPAT2 discovery paper includes hepatic steatosis in affected individuals.
Endocrine 2
Diabetes mellitus FREQUENT Diabetes mellitus (HP:0000819)
Show evidence (1 reference)
ORPHA:528 SUPPORT Other
"HP:0000819 | Diabetes mellitus | Frequent (79-30%)"
Orphanet records diabetes mellitus as frequent.
Hyperinsulinemia OCCASIONAL Hyperinsulinemia (HP:0000842)
Show evidence (1 reference)
ORPHA:528 SUPPORT Other
"HP:0000842 | Hyperinsulinemia | Occasional (29-5%)"
Orphanet records hyperinsulinemia as occasional.
Integument 2
Hypertrichosis FREQUENT Hypertrichosis (HP:0000998)
Show evidence (1 reference)
ORPHA:528 SUPPORT Other
"HP:0000998 | Hypertrichosis | Frequent (79-30%)"
Orphanet records hypertrichosis as frequent.
Acanthosis nigricans OCCASIONAL Acanthosis nigricans (HP:0000956)
Show evidence (2 references)
ORPHA:528 SUPPORT Other
"HP:0000956 | Acanthosis nigricans | Occasional (29-5%)"
Orphanet records acanthosis nigricans as occasional.
PMID:11479539 SUPPORT Human Clinical
"acanthosis nigricans, hyperandrogenism"
The BSCL2 discovery paper lists acanthosis nigricans among clinical features.
Metabolism 3
Insulin resistance VERY_FREQUENT Insulin resistance (HP:0000855)
Show evidence (1 reference)
ORPHA:528 SUPPORT Other
"HP:0000855 | Insulin resistance | Very frequent (99-80%)"
Orphanet records insulin resistance as very frequent.
Hypertriglyceridemia FREQUENT Hypertriglyceridemia (HP:0002155)
Show evidence (1 reference)
ORPHA:528 SUPPORT Other
"HP:0002155 | Hypertriglyceridemia | Frequent (79-30%)"
Orphanet records hypertriglyceridemia as frequent.
CGL4 elevated creatine kinase Elevated circulating creatine kinase concentration (HP:0003236)
Show evidence (1 reference)
PMID:26239609 SUPPORT Human Clinical
"congenital myopathy with high serum levels of creatine kinase"
The CGL review links congenital myopathy in CGL4 with high serum creatine kinase.
Musculoskeletal 2
Lipodystrophy VERY_FREQUENT Lipodystrophy (HP:0009125)
Show evidence (1 reference)
ORPHA:528 SUPPORT Other
"HP:0009125 | Lipodystrophy | Very frequent (99-80%)"
Orphanet records lipodystrophy as very frequent.
CGL4 congenital myopathy Myopathy (HP:0003198)
Show evidence (1 reference)
PMID:26239609 SUPPORT Human Clinical
"congenital myopathy with high serum levels of creatine kinase"
The CGL review summarizes congenital myopathy with high CK in reported CGL4 patients.
Nervous System 1
Intellectual disability FREQUENT Intellectual disability (HP:0001249)
Show evidence (2 references)
ORPHA:528 SUPPORT Other
"HP:0001249 | Intellectual disability | Frequent (79-30%)"
Orphanet records intellectual disability as frequent.
PMID:12362029 SUPPORT Human Clinical
"BSCL2 had a significantly higher prevalence of intellectual impairment"
The genotype-phenotype cohort supports intellectual impairment, particularly in BSCL2-associated disease.
Other 2
Skeletal muscle hypertrophy VERY_FREQUENT Skeletal muscle hypertrophy (HP:0003712)
Show evidence (1 reference)
ORPHA:528 SUPPORT Other
"HP:0003712 | Skeletal muscle hypertrophy | Very frequent (99-80%)"
Orphanet records skeletal muscle hypertrophy as very frequent.
Adipose tissue loss VERY_FREQUENT Adipose tissue loss (HP:0008887)
Show evidence (1 reference)
ORPHA:528 SUPPORT Other
"HP:0008887 | Adipose tissue loss | Very frequent (99-80%)"
Orphanet records adipose tissue loss as very frequent.
🧬

Genetic Associations

4
AGPAT2 pathogenic variants (Causative biallelic pathogenic variants)
Show evidence (1 reference)
PMID:11967537 SUPPORT Human Clinical
"several different mutations of the gene (AGPAT2) encoding"
The AGPAT2 discovery paper identified AGPAT2 mutations in linked families.
BSCL2 pathogenic variants (Causative biallelic pathogenic variants)
Show evidence (1 reference)
PMID:11479539 SUPPORT Human Clinical
"disclosed mutations in a gene homologous to the murine guanine"
The BSCL2 discovery paper identified mutations in the chromosome 11q13 disease gene.
CAV1 pathogenic variants (Causative biallelic pathogenic variants)
Show evidence (1 reference)
PMID:26239609 SUPPORT Other
"associated with mutations in CAV1"
The review summarizes CAV1 as the disease gene for CGL type 3.
CAVIN1 pathogenic variants (Causative biallelic pathogenic variants)
Show evidence (1 reference)
PMID:26239609 SUPPORT Other
"is caused by mutations in PTRF"
The review summarizes PTRF, now CAVIN1, as the disease gene for CGL type 4.
💊

Treatments

5
Metreleptin replacement therapy
Action: Pharmacotherapy NCIT:C15986
Agent: metreleptin ↗
Metreleptin, a recombinant leptin analogue, is used with dietary changes to improve metabolic complications in generalized lipodystrophy, including diabetes, hypertriglyceridemia, and hepatic steatosis.
Mechanism Target:
INHIBITS Hypoleptinemia-driven metabolic dysregulation — Leptin replacement counteracts severe leptin deficiency and improves metabolic control.
Show evidence (1 reference)
PMID:26239609 SUPPORT Other
"replacement therapy can dramatically improve metabolic complications"
The review summarizes metreleptin's benefit for CGL metabolic complications.
Show evidence (2 references)
PMID:25734254 SUPPORT Human Clinical
"approved in the United States for generalized lipodystrophy"
The prospective NIH study describes metreleptin approval for generalized lipodystrophy.
PMID:25734254 SUPPORT Human Clinical
"metreleptin decreased HbA1c"
The clinical study supports improved glycemic control during metreleptin treatment.
Low-fat diet and exercise
Action: dietary intervention MAXO:0000088
Dietary management with a low-fat diet, adequate growth calories for children, and regular physical activity is part of supportive metabolic management, although controlled-trial evidence is limited.
Mechanism Target:
INHIBITS Ectopic triglyceride accumulation — Dietary fat restriction aims to reduce chylomicronemia and triglyceride burden.
Show evidence (1 reference)
PMID:26239609 SUPPORT Other
"Dietary management is of extreme importance"
The review supports dietary management as an important supportive intervention.
Show evidence (1 reference)
PMID:26239609 SUPPORT Other
"encouraged to follow a high carbohydrate, low-fat diet"
The review describes low-fat dietary guidance for CGL.
Conventional diabetes and hyperlipidemia therapy
Action: Pharmacotherapy NCIT:C15986
Conventional pharmacotherapy for diabetes mellitus and hyperlipidemia is used to manage metabolic complications alongside disease-specific leptin replacement where appropriate.
Mechanism Target:
MODULATES Severe insulin resistance — Diabetes pharmacotherapy addresses severe insulin resistance and hyperglycemia.
Show evidence (1 reference)
PMID:26239609 SUPPORT Other
"metformin and sulphonylureas are the first-line therapy for diabetes mellitus"
The review describes first-line conventional diabetes pharmacotherapy.
MODULATES Ectopic triglyceride accumulation — Lipid-lowering therapy addresses severe hypertriglyceridemia.
Show evidence (1 reference)
PMID:26239609 SUPPORT Other
"can be treated with fibric acid derivatives"
The review describes fibrate-class therapy for extreme hypertriglyceridemia.
Show evidence (1 reference)
PMID:26239609 SUPPORT Other
"conventional therapy for hyperlipidaemia and diabetes mellitus"
The review places conventional hyperlipidemia and diabetes therapy in CGL management.
CGL4 beta-blocker and anti-arrhythmic therapy
Action: Pharmacotherapy NCIT:C15986
Agent: beta-adrenergic antagonist ↗
Patients with CAVIN1/PTRF-associated type 4 disease may need avoidance of strenuous exercise plus beta-adrenergic blockers or other anti-arrhythmic medications to prevent catecholaminergic polymorphic ventricular tachycardia.
Mechanism Target:
INHIBITS CGL4 cardiac arrhythmia risk — Beta-blockers and anti-arrhythmic drugs are used to reduce CGL4 ventricular arrhythmia risk.
Show evidence (1 reference)
PMID:26239609 SUPPORT Human Clinical
"anti-arrhythmic medications to prevent catecholaminergic polymorphic ventricular tachycardia"
The review states that anti-arrhythmic medications are used to prevent CPVT in CGL4.
Target Phenotypes: Arrhythmia ↗
Show evidence (1 reference)
PMID:26239609 SUPPORT Human Clinical
"β-adrenergic blockers and other anti-arrhythmic medications to prevent catecholaminergic polymorphic ventricular tachycardia"
The CGL review recommends beta-blockers and other anti-arrhythmic medications for CGL4 arrhythmia prevention.
Genetic counseling
Action: genetic counseling MAXO:0000079
Genetic counseling is indicated for affected families because established subtypes are autosomal recessive and molecular diagnosis informs recurrence risk and subtype-specific anticipatory guidance.
Show evidence (1 reference)
PMID:12362029 SUPPORT Human Clinical
"clear implications for genetic counselling."
The genotype-phenotype study emphasizes genetic counseling implications of molecular diagnosis.
🔬

Biochemical Markers

3
Hypertriglyceridemia (INCREASED)
Context: Circulating triglycerides are increased because adipose storage is severely impaired and lipid handling is diverted to non-adipose tissues.
Pathograph Readouts
Readout Of Ectopic triglyceride accumulation Positive Diagnostic
Elevated circulating triglycerides report the failed adipose-storage and ectopic triglyceride branch of CGL.
Show evidence (1 reference)
PMID:26239609 SUPPORT Other
"Hypertriglyceridaemia is present in >70% of patients with CGL"
Review identifies hypertriglyceridemia as a common circulating biochemical abnormality in CGL.
Show evidence (1 reference)
PMID:26239609 SUPPORT Other
"Hypertriglyceridaemia is present in >70% of patients with CGL"
The review summarizes hypertriglyceridemia prevalence in CGL.
Low leptin concentration (DECREASED)
Context: Near-total adipose tissue loss produces markedly reduced leptin levels, supporting replacement therapy in generalized lipodystrophy.
Pathograph Readouts
Readout Of Hypoleptinemia-driven metabolic dysregulation Negative Diagnostic
Low circulating leptin reports the hypoleptinemic metabolic branch caused by near-total adipose tissue loss.
Show evidence (1 reference)
PMID:26239609 SUPPORT Other
"leptin levels were 0.63 ng/ml"
Review provides low circulating leptin measurements in CGL patients.
Show evidence (1 reference)
PMID:26239609 SUPPORT Other
"leptin levels were 0.63 ng/ml"
The review summarizes low leptin levels in patients with CGL.
Hyperinsulinemia (INCREASED)
Context: Hyperinsulinemia is a compensatory biochemical feature of severe insulin resistance.
Pathograph Readouts
Readout Of Severe insulin resistance Positive Diagnostic
Elevated circulating insulin reports compensation for severe insulin resistance.
Show evidence (1 reference)
PMID:26239609 SUPPORT Other
"The majority of patients develop hyperinsulinaemia"
Review identifies hyperinsulinemia as a common biochemical feature of CGL insulin resistance.
Show evidence (1 reference)
PMID:26239609 SUPPORT Other
"The majority of patients develop hyperinsulinaemia"
The review states that most patients develop hyperinsulinemia.
{ }

Source YAML

click to show 
name: Berardinelli-Seip Congenital Lipodystrophy
category: Mendelian
creation_date: '2026-05-04T00:00:00Z'
updated_date: '2026-05-21T21:29:20Z'
synonyms:
- Congenital generalized lipodystrophy
- Berardinelli-Seip syndrome
- BSCL
- CGL
description: >
  Berardinelli-Seip congenital lipodystrophy is a rare autosomal recessive
  generalized lipodystrophy with near-total adipose tissue loss from birth or
  early infancy, muscular hypertrophy, severe insulin resistance,
  hypertriglyceridemia, hepatic steatosis, hepatomegaly, and early diabetes.
  The four established molecular subtypes are caused by biallelic pathogenic
  variants in AGPAT2, BSCL2, CAV1, and CAVIN1/PTRF. These genes converge on
  impaired triglyceride or phospholipid handling, lipid-droplet biology,
  adipocyte differentiation, and caveola formation in adipocytes. Failure to
  store triglycerides in adipose tissue diverts lipid to liver and skeletal
  muscle and combines with severe leptin deficiency to drive the metabolic
  phenotype. Treatment is supportive and metabolic, including dietary
  management, conventional diabetes and hyperlipidemia therapy, and metreleptin
  replacement for generalized lipodystrophy.
disease_term:
  preferred_term: Berardinelli-Seip congenital lipodystrophy
  term:
    id: MONDO:0018883
    label: Berardinelli-Seip congenital lipodystrophy
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0018883
      label: Berardinelli-Seip congenital lipodystrophy
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
parents:
- Hereditary lipodystrophy
- Disorder of development or morphogenesis
has_subtypes:
- name: CGL1
  display_name: Type 1 (AGPAT2)
  description: >
    Type 1 congenital generalized lipodystrophy is the AGPAT2-associated form
    corresponding to OMIM 608594. AGPAT2 encodes a lysophosphatidic acid
    acyltransferase required for phosphatidic acid generation during
    triglyceride and glycerophospholipid biosynthesis in adipose tissue.
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "type 1 is associated with AGPAT2 mutations"
    explanation: The review defines CGL type 1 as the AGPAT2-associated subtype.
  - reference: PMID:11967537
    reference_title: AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "several different mutations of the gene (AGPAT2) encoding"
    explanation: The AGPAT2 discovery study identified AGPAT2 mutations in affected individuals.
- name: CGL2
  display_name: Type 2 (BSCL2/seipin)
  description: >
    Type 2 congenital generalized lipodystrophy is the BSCL2-associated form
    corresponding to OMIM 269700. BSCL2 encodes seipin, an endoplasmic-reticulum
    protein involved in lipid-droplet assembly, lipid homeostasis, and terminal
    adipocyte differentiation.
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "associated with BSCL2 mutations; type 3 is associated"
    explanation: The review defines CGL type 2 as the BSCL2-associated subtype.
  - reference: PMID:11479539
    reference_title: Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "encodes a protein (which we have called seipin)"
    explanation: The BSCL2 discovery study identifies the seipin gene product in families linked to chromosome 11q13.
- name: CGL3
  display_name: Type 3 (CAV1)
  description: >
    Type 3 congenital generalized lipodystrophy is the CAV1-associated form
    corresponding to OMIM 612526. CAV1 encodes caveolin 1, a core caveola
    component needed for caveola-mediated lipid handling and lipid-droplet
    integrity in adipocytes.
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "type 3 is associated with CAV1 mutations"
    explanation: The review defines CGL type 3 as the CAV1-associated subtype.
- name: CGL4
  display_name: Type 4 (CAVIN1/PTRF)
  description: >
    Type 4 congenital generalized lipodystrophy is the CAVIN1/PTRF-associated
    form corresponding to OMIM 613327. CAVIN1 was historically named PTRF and is
    required for caveola biogenesis and adipose tissue expandability.
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "type 4 is associated with PTRF mutations"
    explanation: The review defines CGL type 4 as the PTRF/CAVIN1-associated subtype.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >
    Berardinelli-Seip congenital lipodystrophy is inherited as an autosomal
    recessive disorder across the established molecular subtypes.
  evidence:
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet records autosomal recessive inheritance.
  - reference: PMID:11967537
    reference_title: AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Congenital generalized lipodystrophy is an autosomal recessive disorder"
    explanation: The AGPAT2 discovery study states the autosomal recessive inheritance pattern.
prevalence:
- population: Worldwide
  percentage: 1-9 per 1,000,000
  notes: >
    Orphanet reports worldwide point prevalence in the 1-9 per 1,000,000 range.
  evidence:
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 1 000 000 | Worldwide | Point prevalence"
    explanation: Orphanet provides the worldwide point-prevalence class.
progression:
- phase: Neonatal to childhood onset
  age_range: Birth to childhood
  notes: >
    Generalized lipoatrophy is usually recognized at birth or in infancy, with
    metabolic complications often emerging during infancy, childhood, or puberty.
  evidence:
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Neonatal"
    explanation: Orphanet records neonatal onset as one of the onset categories.
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "near complete lack of adipose tissue from"
    explanation: The review states that CGL is characterized by near-complete adipose tissue absence from birth.
pathophysiology:
- name: AGPAT2 acylglycerol synthesis defect
  description: >
    AGPAT2 pathogenic variants impair lysophosphatidic-acid acylation to
    phosphatidic acid, a key step in triacylglycerol and glycerophospholipid
    synthesis. In adipocytes this limits normal triglyceride synthesis and
    storage.
  genes:
  - preferred_term: AGPAT2
    term:
      id: hgnc:325
      label: AGPAT2
  biological_processes:
  - preferred_term: triglyceride biosynthetic process
    term:
      id: GO:0019432
      label: triglyceride biosynthetic process
    modifier: DECREASED
  molecular_functions:
  - preferred_term: lysophosphatidic acid acyltransferase activity
    term:
      id: GO:0042171
      label: lysophosphatidic acid acyltransferase activity
    modifier: DECREASED
  cell_types:
  - preferred_term: adipocyte
    term:
      id: CL:0000136
      label: adipocyte
  chemical_entities:
  - preferred_term: phosphatidic acid
    term:
      id: CHEBI:16337
      label: phosphatidic acid
    modifier: DECREASED
  evidence:
  - reference: PMID:11967537
    reference_title: AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "AGPAT2 enzyme catalyzes the acylation"
    explanation: The AGPAT2 discovery paper defines the affected enzymatic step.
  - reference: PMID:11967537
    reference_title: AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "by inhibiting triacylglycerol synthesis and storage in adipocytes."
    explanation: The paper links AGPAT2 mutations to impaired triacylglycerol storage in adipocytes.
  downstream:
  - target: Generalized adipose tissue loss
    description: Impaired adipocyte triglyceride synthesis and storage contributes to generalized adipose tissue loss.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:11967537
      reference_title: AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "by inhibiting triacylglycerol synthesis and storage in adipocytes."
      explanation: The AGPAT2 discovery paper links impaired adipocyte triacylglycerol storage to congenital generalized lipodystrophy.
- name: BSCL2 seipin lipid-droplet dysregulation
  description: >
    BSCL2 encodes seipin, an endoplasmic-reticulum protein that participates in
    lipid-droplet assembly and terminal adipocyte differentiation. Loss of
    seipin disrupts regulated lipid-droplet biology and adipogenesis.
  genes:
  - preferred_term: BSCL2
    term:
      id: hgnc:15832
      label: BSCL2
  biological_processes:
  - preferred_term: fat cell differentiation
    term:
      id: GO:0045444
      label: fat cell differentiation
    modifier: DECREASED
  - preferred_term: lipid droplet organization
    term:
      id: GO:0034389
      label: lipid droplet organization
    modifier: DECREASED
  cell_types:
  - preferred_term: adipocyte
    term:
      id: CL:0000136
      label: adipocyte
  locations:
  - preferred_term: lipid droplet
    term:
      id: GO:0005811
      label: lipid droplet
    modifier: DECREASED
  evidence:
  - reference: PMID:11479539
    reference_title: Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "variants are null mutations"
    explanation: The BSCL2 discovery paper supports severe disruption of seipin in affected families.
  - reference: PMID:22269949
    reference_title: Berardinelli-seip congenital lipodystrophy 2/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Bscl2(-/-) mice develop"
    explanation: The mouse knockout model recapitulates severe white-adipose lipodystrophy.
  - reference: PMID:22269949
    reference_title: Berardinelli-seip congenital lipodystrophy 2/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "a striking failure in terminal"
    explanation: Cell differentiation experiments support seipin loss as a terminal adipocyte differentiation defect.
  downstream:
  - target: Generalized adipose tissue loss
    description: Failed adipocyte differentiation and lipid-droplet maintenance reduces adipose tissue mass.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Seipin loss disrupts terminal adipocyte differentiation.
    - Lipid-droplet loss and adipose transcriptional silencing reduce white adipose tissue.
    evidence:
    - reference: PMID:22269949
      reference_title: Berardinelli-seip congenital lipodystrophy 2/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Bscl2(-/-) mice develop severe lipodystrophy of white adipose tissue (WAT), dyslipidemia, insulin resistance, and hepatic steatosis."
      explanation: Bscl2 knockout mice recapitulate severe white-adipose lipodystrophy and metabolic complications.
    - reference: PMID:22269949
      reference_title: Berardinelli-seip congenital lipodystrophy 2/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "a striking failure in terminal differentiation due to unbridled cyclic AMP (cAMP)-dependent protein kinase A (PKA)-activated lipolysis"
      explanation: Cell differentiation experiments support terminal adipocyte differentiation failure as the intermediate.
  - target: Intellectual disability
    description: BSCL2-associated disease has higher risk of intellectual impairment than AGPAT2-associated disease.
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:12362029
      reference_title: Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "BSCL2 had a significantly higher prevalence of intellectual impairment"
      explanation: Human genotype-phenotype data support intellectual impairment as enriched in BSCL2-associated disease, while the mechanism is not resolved.
- name: CAV1 caveola and lipid-droplet defect
  description: >
    CAV1 encodes caveolin 1, a major caveola component. CAV1 deficiency disrupts
    caveola-dependent fatty-acid and cholesterol handling and reduces the
    ability of adipocytes to expand lipid droplets.
  genes:
  - preferred_term: CAV1
    term:
      id: hgnc:1527
      label: CAV1
  biological_processes:
  - preferred_term: caveola assembly
    term:
      id: GO:0070836
      label: caveola assembly
    modifier: DECREASED
  - preferred_term: lipid droplet organization
    term:
      id: GO:0034389
      label: lipid droplet organization
    modifier: DECREASED
  cell_types:
  - preferred_term: adipocyte
    term:
      id: CL:0000136
      label: adipocyte
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Type 3 CGL, (OMIM #612526)"
    explanation: The review identifies type 3 CGL as the CAV1-associated subtype.
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "enables the expansion of lipid droplet size"
    explanation: The review links caveolin 1 to lipid-droplet expansion in adipocytes.
  downstream:
  - target: Generalized adipose tissue loss
    description: Defective caveola and lipid-droplet expansion impairs adipose tissue maintenance.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - CAV1-dependent caveolae maintain lipid-droplet integrity and expansion.
    - Impaired adipocyte lipid-droplet expansion reduces adipose tissue maintenance.
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "enables the expansion of lipid droplet size"
      explanation: Review links caveolin 1 to lipid-droplet expansion, supporting the adipose-loss mechanism.
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Metabolic adipose tissue was absent"
      explanation: The reported CAV1-associated patient had absent metabolic adipose tissue.
- name: CAVIN1 caveola biogenesis defect
  description: >
    CAVIN1, historically named PTRF, is required for caveola biogenesis and
    caveola stabilization. Biallelic pathogenic variants cause type 4 CGL with
    progressive lipodystrophy and additional muscle and cardiac involvement.
  genes:
  - preferred_term: CAVIN1
    term:
      id: hgnc:9688
      label: CAVIN1
  biological_processes:
  - preferred_term: caveola assembly
    term:
      id: GO:0070836
      label: caveola assembly
    modifier: DECREASED
  cell_types:
  - preferred_term: adipocyte
    term:
      id: CL:0000136
      label: adipocyte
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Type 4 CGL (OMIM #613327)"
    explanation: The review identifies type 4 CGL as the PTRF/CAVIN1-associated subtype.
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "an essential factor in the biogenesis of caveolae"
    explanation: The review states that PTRF/CAVIN1 is essential for caveola biogenesis.
  downstream:
  - target: Generalized adipose tissue loss
    description: Caveola biogenesis failure disrupts adipocyte lipid handling and tissue expandability.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - CAVIN1/PTRF is required for caveola biogenesis and stabilization.
    - Caveola loss impairs adipocyte differentiation and tissue expandability.
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "an essential factor in the biogenesis of caveolae"
      explanation: Review identifies CAVIN1/PTRF as essential for caveola biogenesis.
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Cavin-1 also regulates adipocyte differentiation and is a determinant of adipose tissue expandability."
      explanation: Review links CAVIN1 to adipocyte differentiation and tissue expandability.
  - target: CGL4 congenital myopathy
    description: CAVIN1/PTRF-associated type 4 disease includes congenital myopathy.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "patients have congenital myopathy with high serum levels of creatine kinase."
      explanation: Review of reported CGL4 patients supports congenital myopathy downstream of CAVIN1/PTRF disease.
  - target: CGL4 elevated creatine kinase
    description: CAVIN1/PTRF-associated myopathy is accompanied by high serum creatine kinase.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "patients have congenital myopathy with high serum levels of creatine kinase."
      explanation: Review of reported CGL4 patients supports elevated creatine kinase accompanying congenital myopathy.
  - target: CGL4 cardiac arrhythmia risk
    description: CAVIN1/PTRF-associated type 4 disease predisposes to serious ventricular arrhythmias.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "predisposition to serious arrhythmias such as catecholaminergic polymorphic ventricular tachycardia, long QT interval and sudden death"
      explanation: Review of reported CGL4 patients supports serious arrhythmia risk downstream of CAVIN1/PTRF disease.
- name: Generalized adipose tissue loss
  description: >
    The shared cellular outcome is near-total loss of adipose tissue and
    inability to maintain normal triglyceride-storing adipocyte depots.
  cell_types:
  - preferred_term: adipocyte
    term:
      id: CL:0000136
      label: adipocyte
    modifier: DECREASED
  locations:
  - preferred_term: adipose tissue
    term:
      id: UBERON:0001013
      label: adipose tissue
    modifier: DECREASED
  evidence:
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "generalized lipoatrophy with acromegaloid features"
    explanation: Orphanet's definition supports generalized lipoatrophy as a core feature.
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "near complete lack of adipose tissue from"
    explanation: The review describes near-complete adipose tissue absence in CGL.
  downstream:
  - target: Lipodystrophy
    description: Near-total adipose loss clinically manifests as generalized lipodystrophy.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:528
      reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0009125 | Lipodystrophy | Very frequent (99-80%)"
      explanation: Orphanet records lipodystrophy as a very frequent phenotype of congenital generalized lipodystrophy.
  - target: Adipose tissue loss
    description: Loss of adipocytes produces the HPO adipose tissue loss phenotype.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:528
      reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0008887 | Adipose tissue loss | Very frequent (99-80%)"
      explanation: Orphanet records adipose tissue loss as a very frequent phenotype.
  - target: Ectopic triglyceride accumulation
    description: Inability to store triglyceride in adipose tissue diverts lipid to non-adipose organs.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Near-total adipose loss limits efficient storage of circulating triglycerides.
    - Excess triglycerides spill over to liver and skeletal muscle.
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "owing to the inability to store triglycerides in adipose tissue."
      explanation: Review identifies failure of adipose triglyceride storage as the driver of ectopic triglyceride accumulation.
  - target: Hypoleptinemia-driven metabolic dysregulation
    description: Near-total adipose tissue loss markedly reduces leptin production.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "secondary to near total loss of fat."
      explanation: Review states that markedly reduced leptin levels are secondary to near-total fat loss.
  - target: Low leptin concentration
    description: Near-total adipose tissue loss lowers circulating leptin.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "leptin levels were 0.63 ng/ml"
      explanation: Review provides low leptin measurements in CGL patients.
  - target: Skeletal muscle hypertrophy
    description: Loss of subcutaneous fat and the CGL body habitus present clinically as extreme muscularity or muscle hypertrophy.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "generalized lack of body fat with extreme muscularity from birth"
      explanation: Review diagnostic criteria link generalized fat loss with extreme muscularity.
    - reference: ORPHA:528
      reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0003712 | Skeletal muscle hypertrophy | Very frequent (99-80%)"
      explanation: Orphanet records skeletal muscle hypertrophy as very frequent.
  - target: Hypertrichosis
    description: Hypertrichosis is a recurrent syndromic feature of congenital generalized lipodystrophy, but the cached evidence does not resolve a single mechanism.
    causal_link_type: UNKNOWN
    evidence:
    - reference: ORPHA:528
      reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000998 | Hypertrichosis | Frequent (79-30%)"
      explanation: Orphanet records hypertrichosis as frequent in congenital generalized lipodystrophy.
- name: Ectopic triglyceride accumulation
  description: >
    Because adipose tissue cannot efficiently store circulating triglycerides,
    excess lipid accumulates in liver and skeletal muscle, causing steatosis,
    hepatomegaly, hypertriglyceridemia, and downstream insulin resistance.
  chemical_entities:
  - preferred_term: triglyceride
    term:
      id: CHEBI:17855
      label: triglyceride
    modifier: INCREASED
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  - preferred_term: cell of skeletal muscle
    term:
      id: CL:0000188
      label: cell of skeletal muscle
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
    modifier: INCREASED
  - preferred_term: skeletal muscle tissue
    term:
      id: UBERON:0001134
      label: skeletal muscle tissue
    modifier: INCREASED
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The major mechanism for developing metabolic complications in CGL is related to the near total lack of adipose tissue"
    explanation: The review states the central mechanism for metabolic complications.
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "spillover of excess triglycerides to other organs such as the liver and skeletal muscles"
    explanation: The review explains ectopic triglyceride spillover into liver and skeletal muscle.
  downstream:
  - target: Hepatic steatosis
    description: Ectopic triglyceride accumulation in hepatocytes produces hepatic steatosis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "excess triglyceride accumulation in the liver and skeletal muscle"
      explanation: Review identifies excess hepatic triglyceride accumulation as the main metabolic mechanism.
  - target: Hepatomegaly
    description: Hepatic lipid accumulation contributes to liver enlargement.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Ectopic hepatic triglyceride accumulation causes hepatic steatosis.
    - Hepatic steatosis can enlarge the liver.
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Patients can have liver enlargement due to hepatic steatosis in infancy."
      explanation: Review links hepatic steatosis to liver enlargement in CGL.
  - target: Hypertriglyceridemia
    description: Impaired adipose storage and altered lipid handling contribute to circulating hypertriglyceridemia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Hypertriglyceridaemia is present in >70% of patients with CGL"
      explanation: Review supports hypertriglyceridemia as a common metabolic consequence of the triglyceride storage defect.
  - target: Insulin resistance
    description: Ectopic lipid accumulation is a major driver of severe insulin resistance.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "However, how hepatic steatosis and increased intramyocellular lipids induce insulin resistance has not been elucidated."
      explanation: Review supports the ectopic lipid-to-insulin-resistance link while noting unresolved intermediates.
  - target: Severe insulin resistance
    description: >
      Hepatic steatosis and intramyocellular lipid accumulation contribute to
      the severe insulin-resistance mechanism, although the intervening
      molecular steps remain incompletely defined.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "However, how hepatic steatosis and increased intramyocellular lipids induce insulin resistance has not been elucidated."
      explanation: >
        The review supports a causal connection from ectopic lipid deposition to
        insulin resistance while explicitly noting that the precise intermediates
        are unresolved.
- name: Hypoleptinemia-driven metabolic dysregulation
  description: >
    Near-total adipose tissue loss markedly lowers leptin levels. Severe leptin
    deficiency can increase appetite and worsen diabetes,
    hypertriglyceridemia, and hepatic steatosis.
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Profound hypoleptinaemia further exacerbates metabolic"
    explanation: The review links profound leptin deficiency to worsened metabolic derangements.
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "by inducing hyperphagia."
    explanation: The review identifies hyperphagia as one mechanism of leptin-deficiency-mediated metabolic worsening.
  downstream:
  - target: Insulin resistance
    description: Severe leptin deficiency worsens metabolic insulin resistance.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Severe hypoleptinemia induces hyperphagia.
    - Hyperphagia exacerbates metabolic derangements and insulin resistance.
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Profound hypoleptinaemia further exacerbates metabolic derangements by inducing a voracious appetite."
      explanation: Review links profound leptin deficiency to worsened metabolic derangements through hyperphagia.
  - target: Hypertriglyceridemia
    description: Leptin deficiency worsens triglyceride dysregulation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Profound hypoleptinaemia further exacerbates metabolic derangements by inducing a voracious appetite."
      explanation: Review supports hypoleptinemia as an exacerbating driver of metabolic derangements including hypertriglyceridemia.
  - target: Diabetes mellitus
    description: Worsened metabolic derangement contributes to diabetes.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Patients develop metabolic complications, such as diabetes mellitus, hypertriglyceridaemia and hepatic steatosis later in life."
      explanation: Review places diabetes among downstream metabolic complications worsened by the lipodystrophy/hypoleptinemia state.
- name: Severe insulin resistance
  description: >
    Ectopic lipid accumulation and leptin deficiency produce extreme insulin
    resistance. This drives hyperinsulinemia, acanthosis nigricans, glucose
    intolerance, and diabetes.
  biological_processes:
  - preferred_term: insulin receptor signaling pathway
    term:
      id: GO:0008286
      label: insulin receptor signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:11967537
    reference_title: AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "marked paucity of adipose tissue, extreme insulin resistance,"
    explanation: The AGPAT2 discovery paper includes extreme insulin resistance in the clinical phenotype.
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "muscle hypertrophy, insulin resistance, hypertriglyceridemia"
    explanation: Orphanet includes insulin resistance as a defining feature.
  downstream:
  - target: Insulin resistance
    description: The mechanism directly produces the clinical insulin-resistance phenotype.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:528
      reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000855 | Insulin resistance | Very frequent (99-80%)"
      explanation: Orphanet records insulin resistance as very frequent in congenital generalized lipodystrophy.
  - target: Hyperinsulinemia
    description: Pancreatic compensation for insulin resistance increases circulating insulin.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The majority of patients develop hyperinsulinaemia"
      explanation: Review supports hyperinsulinemia as a common compensatory feature in CGL.
  - target: Diabetes mellitus
    description: Severe insulin resistance predisposes to diabetes mellitus.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "~45% develop diabetes mellitus during the pubertal years."
      explanation: Review supports diabetes as a downstream clinical complication of severe insulin resistance in CGL.
  - target: Acanthosis nigricans
    description: Chronic insulin resistance can produce acanthosis nigricans.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Acanthosis nigricans develops during early childhood or after puberty"
      explanation: Review supports acanthosis nigricans as a cutaneous manifestation in the insulin-resistance phase.
  - target: Hypertrophic cardiomyopathy
    description: Severe cardiometabolic disease can include hypertrophic cardiomyopathy, but the cached evidence does not resolve a single intermediate mechanism.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:12362029
      reference_title: Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "hypertrophic cardiomyopathy were significant contributors to morbidity"
      explanation: Human genotype-phenotype cohort supports hypertrophic cardiomyopathy as a morbidity contributor in BSCL.
phenotypes:
- name: Insulin resistance
  frequency: VERY_FREQUENT
  description: Severe insulin resistance is a core metabolic manifestation.
  phenotype_term:
    preferred_term: Insulin resistance
    term:
      id: HP:0000855
      label: Insulin resistance
  evidence:
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000855 | Insulin resistance | Very frequent (99-80%)"
    explanation: Orphanet records insulin resistance as very frequent.
- name: Hepatomegaly
  frequency: VERY_FREQUENT
  description: Liver enlargement is common and reflects hepatic lipid accumulation.
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  evidence:
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002240 | Hepatomegaly | Very frequent (99-80%)"
    explanation: Orphanet records hepatomegaly as very frequent.
- name: Skeletal muscle hypertrophy
  frequency: VERY_FREQUENT
  description: Affected individuals have prominent musculature from loss of subcutaneous fat and muscular hypertrophy.
  phenotype_term:
    preferred_term: Skeletal muscle hypertrophy
    term:
      id: HP:0003712
      label: Skeletal muscle hypertrophy
  evidence:
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003712 | Skeletal muscle hypertrophy | Very frequent (99-80%)"
    explanation: Orphanet records skeletal muscle hypertrophy as very frequent.
- name: Adipose tissue loss
  frequency: VERY_FREQUENT
  description: Near-total adipose tissue loss begins at birth or early infancy.
  phenotype_term:
    preferred_term: Adipose tissue loss
    term:
      id: HP:0008887
      label: Adipose tissue loss
  evidence:
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0008887 | Adipose tissue loss | Very frequent (99-80%)"
    explanation: Orphanet records adipose tissue loss as very frequent.
- name: Lipodystrophy
  frequency: VERY_FREQUENT
  description: The disorder is a generalized lipodystrophy with abnormal adipose tissue morphology and distribution.
  phenotype_term:
    preferred_term: Lipodystrophy
    term:
      id: HP:0009125
      label: Lipodystrophy
  evidence:
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0009125 | Lipodystrophy | Very frequent (99-80%)"
    explanation: Orphanet records lipodystrophy as very frequent.
- name: Diabetes mellitus
  frequency: FREQUENT
  description: Diabetes often develops after severe insulin resistance and metabolic dysregulation.
  phenotype_term:
    preferred_term: Diabetes mellitus
    term:
      id: HP:0000819
      label: Diabetes mellitus
  evidence:
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000819 | Diabetes mellitus | Frequent (79-30%)"
    explanation: Orphanet records diabetes mellitus as frequent.
- name: Hypertrichosis
  frequency: FREQUENT
  description: Increased hair growth is a frequent Orphanet phenotype.
  phenotype_term:
    preferred_term: Hypertrichosis
    term:
      id: HP:0000998
      label: Hypertrichosis
  evidence:
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000998 | Hypertrichosis | Frequent (79-30%)"
    explanation: Orphanet records hypertrichosis as frequent.
- name: Intellectual disability
  frequency: FREQUENT
  description: Intellectual disability is especially enriched in BSCL2-associated CGL.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001249 | Intellectual disability | Frequent (79-30%)"
    explanation: Orphanet records intellectual disability as frequent.
  - reference: PMID:12362029
    reference_title: Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BSCL2 had a significantly higher prevalence of intellectual impairment"
    explanation: The genotype-phenotype cohort supports intellectual impairment, particularly in BSCL2-associated disease.
- name: Hypertriglyceridemia
  frequency: FREQUENT
  description: Hypertriglyceridemia reflects failed adipose triglyceride storage and ectopic lipid handling.
  phenotype_term:
    preferred_term: Hypertriglyceridemia
    term:
      id: HP:0002155
      label: Hypertriglyceridemia
  evidence:
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002155 | Hypertriglyceridemia | Frequent (79-30%)"
    explanation: Orphanet records hypertriglyceridemia as frequent.
- name: Hepatic steatosis
  frequency: OCCASIONAL
  description: Hepatic triglyceride deposition produces fatty liver and may contribute to hepatomegaly.
  phenotype_term:
    preferred_term: Hepatic steatosis
    term:
      id: HP:0001397
      label: Hepatic steatosis
  evidence:
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001397 | Hepatic steatosis | Occasional (29-5%)"
    explanation: Orphanet records hepatic steatosis as occasional.
  - reference: PMID:11967537
    reference_title: AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hypertriglyceridemia, hepatic steatosis and early onset of diabetes."
    explanation: The AGPAT2 discovery paper includes hepatic steatosis in affected individuals.
- name: Acanthosis nigricans
  frequency: OCCASIONAL
  description: Acanthosis nigricans is a cutaneous manifestation of severe insulin resistance.
  phenotype_term:
    preferred_term: Acanthosis nigricans
    term:
      id: HP:0000956
      label: Acanthosis nigricans
  evidence:
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000956 | Acanthosis nigricans | Occasional (29-5%)"
    explanation: Orphanet records acanthosis nigricans as occasional.
  - reference: PMID:11479539
    reference_title: Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "acanthosis nigricans, hyperandrogenism"
    explanation: The BSCL2 discovery paper lists acanthosis nigricans among clinical features.
- name: Hypertrophic cardiomyopathy
  frequency: OCCASIONAL
  description: Hypertrophic cardiomyopathy contributes to morbidity in a subset of patients.
  phenotype_term:
    preferred_term: Hypertrophic cardiomyopathy
    term:
      id: HP:0001639
      label: Hypertrophic cardiomyopathy
  evidence:
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001639 | Hypertrophic cardiomyopathy | Occasional (29-5%)"
    explanation: Orphanet records hypertrophic cardiomyopathy as occasional.
  - reference: PMID:12362029
    reference_title: Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hypertrophic cardiomyopathy were significant contributors"
    explanation: The genotype-phenotype cohort identifies hypertrophic cardiomyopathy as a morbidity contributor.
- name: Hyperinsulinemia
  frequency: OCCASIONAL
  description: Hyperinsulinemia reflects compensation for severe insulin resistance.
  phenotype_term:
    preferred_term: Hyperinsulinemia
    term:
      id: HP:0000842
      label: Hyperinsulinemia
  evidence:
  - reference: ORPHA:528
    reference_title: "Congenital generalized lipodystrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000842 | Hyperinsulinemia | Occasional (29-5%)"
    explanation: Orphanet records hyperinsulinemia as occasional.
- name: CGL4 congenital myopathy
  subtype: CGL4
  description: >
    CAVIN1/PTRF-associated type 4 disease includes congenital myopathy as a
    subtype-distinguishing neuromuscular feature.
  phenotype_term:
    preferred_term: Myopathy
    term:
      id: HP:0003198
      label: Myopathy
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "congenital myopathy with high serum levels of creatine kinase"
    explanation: The CGL review summarizes congenital myopathy with high CK in reported CGL4 patients.
- name: CGL4 elevated creatine kinase
  subtype: CGL4
  description: >
    Elevated serum creatine kinase accompanies the congenital myopathy reported
    in CAVIN1/PTRF-associated type 4 disease.
  phenotype_term:
    preferred_term: Elevated circulating creatine kinase concentration
    term:
      id: HP:0003236
      label: Elevated circulating creatine kinase concentration
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "congenital myopathy with high serum levels of creatine kinase"
    explanation: The CGL review links congenital myopathy in CGL4 with high serum creatine kinase.
- name: CGL4 cardiac arrhythmia risk
  subtype: CGL4
  description: >
    CAVIN1/PTRF-associated type 4 disease has a serious arrhythmia risk that
    can include catecholaminergic polymorphic ventricular tachycardia and long
    QT interval.
  phenotype_term:
    preferred_term: Arrhythmia
    term:
      id: HP:0011675
      label: Arrhythmia
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "predisposition to serious arrhythmias such as catecholaminergic polymorphic ventricular tachycardia, long QT interval and sudden death"
    explanation: The CGL review identifies serious arrhythmias and sudden death as CGL4-specific risks.
biochemical:
- name: Hypertriglyceridemia
  presence: INCREASED
  context: >
    Circulating triglycerides are increased because adipose storage is severely
    impaired and lipid handling is diverted to non-adipose tissues.
  biomarker_term:
    preferred_term: triglyceride
    term:
      id: CHEBI:17855
      label: triglyceride
  readouts:
  - target: Ectopic triglyceride accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated circulating triglycerides report the failed adipose-storage and ectopic triglyceride branch of CGL.
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Hypertriglyceridaemia is present in >70% of patients with CGL"
      explanation: Review identifies hypertriglyceridemia as a common circulating biochemical abnormality in CGL.
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Hypertriglyceridaemia is present in >70% of patients with CGL"
    explanation: The review summarizes hypertriglyceridemia prevalence in CGL.
- name: Low leptin concentration
  presence: DECREASED
  context: >
    Near-total adipose tissue loss produces markedly reduced leptin levels,
    supporting replacement therapy in generalized lipodystrophy.
  biomarker_term:
    preferred_term: leptin
    term:
      id: NCIT:C46081
      label: Leptin
  readouts:
  - target: Hypoleptinemia-driven metabolic dysregulation
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Low circulating leptin reports the hypoleptinemic metabolic branch caused by near-total adipose tissue loss.
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "leptin levels were 0.63 ng/ml"
      explanation: Review provides low circulating leptin measurements in CGL patients.
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "leptin levels were 0.63 ng/ml"
    explanation: The review summarizes low leptin levels in patients with CGL.
- name: Hyperinsulinemia
  presence: INCREASED
  context: >
    Hyperinsulinemia is a compensatory biochemical feature of severe insulin
    resistance.
  biomarker_term:
    preferred_term: insulin
    term:
      id: NCIT:C2271
      label: Insulin
  readouts:
  - target: Severe insulin resistance
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated circulating insulin reports compensation for severe insulin resistance.
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The majority of patients develop hyperinsulinaemia"
      explanation: Review identifies hyperinsulinemia as a common biochemical feature of CGL insulin resistance.
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The majority of patients develop hyperinsulinaemia"
    explanation: The review states that most patients develop hyperinsulinemia.
genetic:
- name: AGPAT2 pathogenic variants
  subtype: CGL1
  gene_term:
    preferred_term: AGPAT2
    term:
      id: hgnc:325
      label: AGPAT2
  association: Causative biallelic pathogenic variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:11967537
    reference_title: AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "several different mutations of the gene (AGPAT2) encoding"
    explanation: The AGPAT2 discovery paper identified AGPAT2 mutations in linked families.
  variants:
  - name: Biallelic AGPAT2 pathogenic variants
    description: Null and missense AGPAT2 variants can reduce or abolish lysophosphatidic acid acyltransferase activity.
    gene:
      preferred_term: AGPAT2
      term:
        id: hgnc:325
        label: AGPAT2
    clinical_significance: PATHOGENIC
    functional_effects:
    - function: AGPAT2 triglyceride biosynthesis
      description: Impairs triacylglycerol synthesis and storage in adipocytes.
      type: loss-of-function
    evidence:
    - reference: PMID:11967537
      reference_title: AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "by inhibiting triacylglycerol synthesis and storage in adipocytes."
      explanation: The paper states the proposed functional effect of AGPAT2 mutations.
- name: BSCL2 pathogenic variants
  subtype: CGL2
  gene_term:
    preferred_term: BSCL2
    term:
      id: hgnc:15832
      label: BSCL2
  association: Causative biallelic pathogenic variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:11479539
    reference_title: Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "disclosed mutations in a gene homologous to the murine guanine"
    explanation: The BSCL2 discovery paper identified mutations in the chromosome 11q13 disease gene.
  variants:
  - name: Biallelic BSCL2 pathogenic variants
    description: Null and missense BSCL2 variants disrupt seipin-dependent lipid-droplet regulation and adipocyte differentiation.
    gene:
      preferred_term: BSCL2
      term:
        id: hgnc:15832
        label: BSCL2
    clinical_significance: PATHOGENIC
    functional_effects:
    - function: Seipin lipid-droplet regulation
      description: Disrupts lipid-droplet organization and terminal adipocyte differentiation.
      type: loss-of-function
    evidence:
    - reference: PMID:22269949
      reference_title: Berardinelli-seip congenital lipodystrophy 2/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "loss of lipid droplets and silencing"
      explanation: Cell-model evidence links seipin loss to lipid-droplet loss and adipocyte transcriptional silencing.
- name: CAV1 pathogenic variants
  subtype: CGL3
  gene_term:
    preferred_term: CAV1
    term:
      id: hgnc:1527
      label: CAV1
  association: Causative biallelic pathogenic variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "associated with mutations in CAV1"
    explanation: The review summarizes CAV1 as the disease gene for CGL type 3.
- name: CAVIN1 pathogenic variants
  subtype: CGL4
  gene_term:
    preferred_term: CAVIN1
    term:
      id: hgnc:9688
      label: CAVIN1
  association: Causative biallelic pathogenic variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "is caused by mutations in PTRF"
    explanation: The review summarizes PTRF, now CAVIN1, as the disease gene for CGL type 4.
treatments:
- name: Metreleptin replacement therapy
  description: >
    Metreleptin, a recombinant leptin analogue, is used with dietary changes to
    improve metabolic complications in generalized lipodystrophy, including
    diabetes, hypertriglyceridemia, and hepatic steatosis.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: metreleptin
      term:
        id: NCIT:C170171
        label: Metreleptin
  target_mechanisms:
  - target: Hypoleptinemia-driven metabolic dysregulation
    treatment_effect: INHIBITS
    description: Leptin replacement counteracts severe leptin deficiency and improves metabolic control.
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "replacement therapy can dramatically improve metabolic complications"
      explanation: The review summarizes metreleptin's benefit for CGL metabolic complications.
  evidence:
  - reference: PMID:25734254
    reference_title: "Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "approved in the United States for generalized lipodystrophy"
    explanation: The prospective NIH study describes metreleptin approval for generalized lipodystrophy.
  - reference: PMID:25734254
    reference_title: "Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "metreleptin decreased HbA1c"
    explanation: The clinical study supports improved glycemic control during metreleptin treatment.
- name: Low-fat diet and exercise
  description: >
    Dietary management with a low-fat diet, adequate growth calories for
    children, and regular physical activity is part of supportive metabolic
    management, although controlled-trial evidence is limited.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  target_mechanisms:
  - target: Ectopic triglyceride accumulation
    treatment_effect: INHIBITS
    description: Dietary fat restriction aims to reduce chylomicronemia and triglyceride burden.
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Dietary management is of extreme importance"
      explanation: The review supports dietary management as an important supportive intervention.
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "encouraged to follow a high carbohydrate, low-fat diet"
    explanation: The review describes low-fat dietary guidance for CGL.
- name: Conventional diabetes and hyperlipidemia therapy
  description: >
    Conventional pharmacotherapy for diabetes mellitus and hyperlipidemia is
    used to manage metabolic complications alongside disease-specific leptin
    replacement where appropriate.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Severe insulin resistance
    treatment_effect: MODULATES
    description: Diabetes pharmacotherapy addresses severe insulin resistance and hyperglycemia.
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "metformin and sulphonylureas are the first-line therapy for diabetes mellitus"
      explanation: The review describes first-line conventional diabetes pharmacotherapy.
  - target: Ectopic triglyceride accumulation
    treatment_effect: MODULATES
    description: Lipid-lowering therapy addresses severe hypertriglyceridemia.
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "can be treated with fibric acid derivatives"
      explanation: The review describes fibrate-class therapy for extreme hypertriglyceridemia.
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "conventional therapy for hyperlipidaemia and diabetes mellitus"
    explanation: The review places conventional hyperlipidemia and diabetes therapy in CGL management.
- name: CGL4 beta-blocker and anti-arrhythmic therapy
  description: >
    Patients with CAVIN1/PTRF-associated type 4 disease may need avoidance of
    strenuous exercise plus beta-adrenergic blockers or other anti-arrhythmic
    medications to prevent catecholaminergic polymorphic ventricular
    tachycardia.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: beta-adrenergic antagonist
      term:
        id: NCIT:C29576
        label: Beta-Adrenergic Antagonist
  target_phenotypes:
  - preferred_term: Arrhythmia
    term:
      id: HP:0011675
      label: Arrhythmia
  target_mechanisms:
  - target: CGL4 cardiac arrhythmia risk
    treatment_effect: INHIBITS
    description: Beta-blockers and anti-arrhythmic drugs are used to reduce CGL4 ventricular arrhythmia risk.
    evidence:
    - reference: PMID:26239609
      reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "anti-arrhythmic medications to prevent catecholaminergic polymorphic ventricular tachycardia"
      explanation: The review states that anti-arrhythmic medications are used to prevent CPVT in CGL4.
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "β-adrenergic blockers and other anti-arrhythmic medications to prevent catecholaminergic polymorphic ventricular tachycardia"
    explanation: The CGL review recommends beta-blockers and other anti-arrhythmic medications for CGL4 arrhythmia prevention.
- name: Genetic counseling
  description: >
    Genetic counseling is indicated for affected families because established
    subtypes are autosomal recessive and molecular diagnosis informs recurrence
    risk and subtype-specific anticipatory guidance.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:12362029
    reference_title: Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "clear implications for genetic counselling."
    explanation: The genotype-phenotype study emphasizes genetic counseling implications of molecular diagnosis.
diagnosis:
- name: Clinical lipodystrophy assessment
  diagnosis_term:
    preferred_term: disease screening
    term:
      id: MAXO:0000124
      label: disease screening
  description: >
    Clinical recognition rests on generalized lack of body fat with extreme
    muscularity from birth or early infancy, supported by body-fat distribution
    assessment when available.
  results: Generalized lack of body fat with extreme muscularity supports CGL.
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "generalized lack of body fat with extreme muscularity from birth"
    explanation: The review summarizes essential clinical diagnostic criteria for CGL.
- name: CGL molecular genetic testing
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: MAXO:0000127
      label: genetic testing
  description: >
    Molecular testing for biallelic pathogenic variants in AGPAT2, BSCL2, CAV1,
    or CAVIN1/PTRF confirms the subtype when pathogenic variants are found.
  results: Biallelic pathogenic variants in a known CGL gene support molecular diagnosis.
  evidence:
  - reference: PMID:26239609
    reference_title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A number of clinical and research laboratories offer genetic testing for CGL."
    explanation: The review supports genetic testing as part of CGL diagnosis.
references:
- reference: ORPHA:528
  title: Congenital generalized lipodystrophy
  found_in:
  - Berardinelli_Seip_Congenital_Lipodystrophy-deep-research-fallback.md
- reference: PMID:20301391
  title: Berardinelli-Seip Congenital Lipodystrophy.
  tags:
  - GeneReviews
  found_in:
  - Berardinelli_Seip_Congenital_Lipodystrophy-deep-research-fallback.md
- reference: PMID:11967537
  title: AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.
  found_in:
  - Berardinelli_Seip_Congenital_Lipodystrophy-deep-research-fallback.md
- reference: PMID:11479539
  title: Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13.
  found_in:
  - Berardinelli_Seip_Congenital_Lipodystrophy-deep-research-fallback.md
- reference: PMID:12362029
  title: Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy.
  found_in:
  - Berardinelli_Seip_Congenital_Lipodystrophy-deep-research-fallback.md
- reference: PMID:22269949
  title: Berardinelli-seip congenital lipodystrophy 2/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation.
  found_in:
  - Berardinelli_Seip_Congenital_Lipodystrophy-deep-research-fallback.md
- reference: PMID:25734254
  title: "Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin."
  found_in:
  - Berardinelli_Seip_Congenital_Lipodystrophy-deep-research-fallback.md
- reference: PMID:26239609
  title: Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
  found_in:
  - Berardinelli_Seip_Congenital_Lipodystrophy-deep-research-fallback.md
📚

References & Deep Research

References

8
ORPHA:528
Congenital generalized lipodystrophy
No top-level findings curated for this source.
PMID:20301391
Berardinelli-Seip Congenital Lipodystrophy.
No top-level findings curated for this source.
PMID:11967537
AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.
No top-level findings curated for this source.
PMID:11479539
Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13.
No top-level findings curated for this source.
PMID:12362029
Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy.
No top-level findings curated for this source.
PMID:22269949
Berardinelli-seip congenital lipodystrophy 2/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation.
No top-level findings curated for this source.
PMID:25734254
Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
No top-level findings curated for this source.
PMID:26239609
Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
No top-level findings curated for this source.

Deep Research

1
Berardinelli-Seip Congenital Lipodystrophy Deep Research Fallback ▸

Berardinelli-Seip Congenital Lipodystrophy Deep Research Fallback

Date: 2026-05-04T12:09Z

Provider Attempts

  • timeout 120 just research-disorder falcon Berardinelli_Seip_Congenital_Lipodystrophy
  • Result: timed out after the bounded 120-second run and was terminated by signal 15.
  • Completed artifact: none.
  • timeout 120 just research-disorder openai Berardinelli_Seip_Congenital_Lipodystrophy
  • Result: timed out after the bounded 120-second run and was terminated by signal 15.
  • Completed artifact: none.

No provider-generated deep-research narrative was available within the bounded runtime. Curation therefore proceeded from regenerated structured Orphanet evidence and fetched PubMed caches, without hand-editing any references_cache/*.md files.

Evidence Scope Used For Curation

Structured Source

  • ORPHA:528 congenital generalized lipodystrophy structured record
  • Exact MONDO cross-reference: MONDO:0018883
  • Inheritance: autosomal recessive
  • Natural history: neonatal, infantile, and childhood onset categories
  • Worldwide point-prevalence band: 1-9 / 1 000 000
  • Frequent or very frequent HPO phenotypes integrated in the YAML: insulin resistance, hepatomegaly, skeletal muscle hypertrophy, adipose tissue loss, lipodystrophy, diabetes mellitus, hypertrichosis, intellectual disability, and hypertriglyceridemia
  • Additional ORPHA phenotypes integrated where mechanistically relevant: hepatic steatosis, acanthosis nigricans, hypertrophic cardiomyopathy, and hyperinsulinemia
  • Cross-references include OMIM 269700, 608594, 612526, and 613327, used to label the four molecular subtype descriptions.

PubMed Records

  • PMID:11967537 Agarwal et al. 2002
  • Identifies AGPAT2 mutations in congenital generalized lipodystrophy linked to 9q34.
  • Supports autosomal recessive inheritance, marked adipose tissue paucity, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis, early diabetes, and impaired triacylglycerol synthesis/storage in adipocytes.
  • PMID:11479539 Magre et al. 2001
  • Identifies the chromosome 11q13 BSCL2/seipin disease gene in Berardinelli-Seip congenital lipodystrophy families.
  • Supports severe disruption of seipin and clinical features including acanthosis nigricans, hepatomegaly, diabetes, muscle hypertrophy, and hypertriglyceridemia.
  • PMID:12362029 Van Maldergem et al. 2002
  • Cohort genotype-phenotype analysis of 70 affected subjects.
  • Supports BSCL2-associated higher prevalence of intellectual impairment, molecular diagnosis, genetic counseling implications, hepatic dysfunction, hyperlipidemia, diabetes, hypertrophic cardiomyopathy, and subtype severity differences.
  • PMID:22269949 Chen et al. 2012
  • Bscl2 knockout mouse and cell differentiation study.
  • Supports severe white-adipose lipodystrophy, dyslipidemia, insulin resistance, hepatic steatosis, failure of terminal adipocyte differentiation, lipid-droplet loss, and activated lipolysis mechanisms.
  • PMID:25734254 Diker-Cohen et al. 2015
  • Prospective, single-arm, open-label metreleptin study in generalized and partial lipodystrophy.
  • Supports metreleptin use in generalized lipodystrophy and reductions in HbA1c and triglycerides.
  • PMID:26239609 Patni and Garg 2015
  • Full-text review of congenital generalized lipodystrophy pathophysiology and treatment.
  • Supports the four subtype genes AGPAT2, BSCL2, CAV1, and PTRF/CAVIN1; convergence on phospholipid/triglyceride synthesis, lipid droplets, and caveolae; ectopic triglyceride accumulation in liver and skeletal muscle; severe hypoleptinemia; dietary management; conventional diabetes and lipid therapy; and metreleptin replacement.

Curation Conclusions

The curated mechanism model treats Berardinelli-Seip congenital lipodystrophy as a genetically heterogeneous but convergent adipocyte lipid-storage disorder. AGPAT2 deficiency impairs phosphatidic acid production for triglyceride and glycerophospholipid synthesis. BSCL2/seipin deficiency disrupts lipid-droplet organization and terminal adipocyte differentiation. CAV1 and CAVIN1/PTRF defects impair caveola structure or biogenesis, reducing adipocyte lipid handling and expandability. These upstream defects cause generalized adipose tissue loss. The inability to store triglyceride in adipose tissue diverts lipid to liver and skeletal muscle, producing hepatic steatosis, hypertriglyceridemia, hepatomegaly, and severe insulin resistance. Near-total adipose loss also causes hypoleptinemia, worsening hyperphagia and metabolic derangement.

Management is metabolic and supportive: metreleptin replacement addresses leptin-deficiency-driven metabolic complications in generalized lipodystrophy; low-fat dietary management aims to reduce triglyceride burden; conventional diabetes and hyperlipidemia therapy treats downstream complications; and genetic counseling is warranted for autosomal recessive recurrence risk and subtype-specific prognosis.